Treatment with anti-CD105 CAR-T cells significantly reduced the volume and weight of tumor in mice, and prolonged the survival of tumor-bearing mice compared with PBS, Utd, Mock, or anti-CD19 CAR-T cells control (Fig. 5c–e). This evidence concerns the gene CD19 and neoplasm.